Skip to main content

Table 5 Summary of demography and medication differences between participants treated with olanzapine monotherapy bearing the rs2011425 non-G allele and G allele

From: The association of genetic polymorphisms in CYP1A2, UGT1A4, and ABCB1 with autonomic nervous system dysfunction in schizophrenia patients treated with olanzapine

 

rs2011425 T/T

rs2011425 G/T, G/G

P

Age (years)

51.77 ± 15.26

44.33 ± 14.08

0.064

Sex (male/female)

7/11

32/41

0.704

Smoking (Nonsmoker/smoker)

17/1

67/6

0.704

BMI (kg/m2)

24.12 ± 4.53

23.60 ± 5.29

0.675

PANSS total score

72.30 ± 16.75

71.61 ± 12.85

0.871

Disease duration (years)

19.86 ± 13.31

17.83 ± 14.83

0.574

CPZeqa (mg/day)

490.41 ± 245.61

494.44 ± 260.03

0.951

BPDeqb (mg/day)

0.81 ± 1.86

0.67 ± 1.57

0.766

DZPeqc (mg/day)

7.97 ± 14.30

6.19 ± 9.19

0.953

  1. Data are presented as mean ± standard deviation values
  2. BMI Body mass index, PANSS Positive and Negative Syndrome Scale
  3. aThe daily dosages of antipsychotic drugs were converted to approximate chlorpromazine equivalents
  4. bThe daily dosages of anticholinergic antiparkinsonian drugs were converted to approximate biperiden equivalents
  5. cThe daily dosages of benzodiazepine were converted to approximate diazepam equivalents
Back to article page

BMC Psychiatry

ISSN: 1471-244X

Contact us